Pre- and post-treatment of α-Tocopherol on cognitive, synaptic plasticity, and mitochondrial disorders of the hippocampus in icv-streptozotocin-induced sporadic Alzheimer’s-like disease in male Wistar rat
Abstract:ObjectiveMost dementia cases in the elderly are caused by Alzheimer’s disease (AD), a complex, progressive neurological disease. Intracerebroventricular (ICV) administration of streptozotocin (STZ) in rat’s results in aberrant brain insulin signaling, oxidative stress, and mitochondrial dysfunction that impair cognition change neural plasticity, and eventually lead to neuronal death. The current study aims to define the neuroprotective action of alpha-tocopherol in enhancing mitochondrial function and the func… Show more
“…Neuronal plasticity is directly related to greater synaptic efficacy achieved through longterm potentiation (LTP). In animals, LTP is the long-term modification in synaptic strength induced by electrical stimulation which is used in AD research studies [48,74]. To further investigate the long-term effects of flickering 40 Hz light and bilateral injection of STZ into the hippocampus on neuronal activity, we assessed basal synaptic transmission and plasticity in perforant hippocampi one month after injection.…”
Section: Discussionmentioning
confidence: 99%
“…Following the tetanic stimuli, the baseline stimulation was resumed, and the recording was carried out for at least 60 minutes. The average of five successive evoked responses was taken at intervals of 10 seconds [48].…”
Section: Field Excitatory Postsynaptic Potential (Fepsp) and Long-ter...mentioning
confidence: 99%
“…Ten consecutive evoked responses were averaged for each paired-pulse stimulation. Various interstimulus intervals were used to determine the fEPSP slope ratio [percentage of the second fEPSP slope/first fEPSP slope; fEPSP2/fEPSP1%] and the population spike amplitude ratio [percentage of the second population spike amplitude to the first population spike amplitude; PS2/PS1%] [48].…”
Alzheimer's disease (AD) is the most prevalent form of dementia and a public health priority. The causes of AD are not completely understood. Pathogenetic factors including mitochondrial dysfunction, oxidative stress, reduced energy status, and compromised ion channels contribute to the onset and progression of the disease. Flickering light therapy in experimental and clinical AD has shown promising outcomes. However, the mechanisms behind the effect of flickering light at the molecular and cellular level has not yet been fully investigated. In this study, we established streptozotocin (STZ)-induced AD models by intracerebroventricular (ICV) injection of STZ in Wistar rats and monitored their memory decline. Sham and AD rats were either exposed or not exposed to 40 Hz flickering light for 7 consecutive days after 7 days of STZ injection. Memory and cognition-related behavioral analysis, pathological, electrophysiological, and biochemical assessment of the brain tissue, and mitochondrial function assays were conducted after the treatment. Cognitive and memory impairment, examined by Morris water maze (MWM), novel object recognition (NOR), and passive avoidance (PA) test, was observed in the STZ-induced AD rats and light treatment improved these behaviors. STZ injection led to significant accumulation of reactive oxygen species (ROS) and amyloid beta (Aβ), decreased serotonin and dopamine levels, and mitochondrial respiration. The 40 Hz flickering light reversed all these parameters in the light treatment group. The synaptic plasticity of STZ-induced AD rats was severely affected, but flickering light prevented the loss of synaptic plasticity and activity in the light-treated AD rats. Additionally, flickering 40 Hz white light elevated the levels of mitochondrial metabolites and the current and possible opening of the mitochondrial calcium-sensitive potassium (mitoBKCa) channel which were significantly downregulated in AD rat neurons. The 40 Hz flickering light restored mitochondrial function and synaptic plasticity of AD rat neurons and improved the cognition of animals; therefore, it can be a promising strategy to reduce AD progression.
“…Neuronal plasticity is directly related to greater synaptic efficacy achieved through longterm potentiation (LTP). In animals, LTP is the long-term modification in synaptic strength induced by electrical stimulation which is used in AD research studies [48,74]. To further investigate the long-term effects of flickering 40 Hz light and bilateral injection of STZ into the hippocampus on neuronal activity, we assessed basal synaptic transmission and plasticity in perforant hippocampi one month after injection.…”
Section: Discussionmentioning
confidence: 99%
“…Following the tetanic stimuli, the baseline stimulation was resumed, and the recording was carried out for at least 60 minutes. The average of five successive evoked responses was taken at intervals of 10 seconds [48].…”
Section: Field Excitatory Postsynaptic Potential (Fepsp) and Long-ter...mentioning
confidence: 99%
“…Ten consecutive evoked responses were averaged for each paired-pulse stimulation. Various interstimulus intervals were used to determine the fEPSP slope ratio [percentage of the second fEPSP slope/first fEPSP slope; fEPSP2/fEPSP1%] and the population spike amplitude ratio [percentage of the second population spike amplitude to the first population spike amplitude; PS2/PS1%] [48].…”
Alzheimer's disease (AD) is the most prevalent form of dementia and a public health priority. The causes of AD are not completely understood. Pathogenetic factors including mitochondrial dysfunction, oxidative stress, reduced energy status, and compromised ion channels contribute to the onset and progression of the disease. Flickering light therapy in experimental and clinical AD has shown promising outcomes. However, the mechanisms behind the effect of flickering light at the molecular and cellular level has not yet been fully investigated. In this study, we established streptozotocin (STZ)-induced AD models by intracerebroventricular (ICV) injection of STZ in Wistar rats and monitored their memory decline. Sham and AD rats were either exposed or not exposed to 40 Hz flickering light for 7 consecutive days after 7 days of STZ injection. Memory and cognition-related behavioral analysis, pathological, electrophysiological, and biochemical assessment of the brain tissue, and mitochondrial function assays were conducted after the treatment. Cognitive and memory impairment, examined by Morris water maze (MWM), novel object recognition (NOR), and passive avoidance (PA) test, was observed in the STZ-induced AD rats and light treatment improved these behaviors. STZ injection led to significant accumulation of reactive oxygen species (ROS) and amyloid beta (Aβ), decreased serotonin and dopamine levels, and mitochondrial respiration. The 40 Hz flickering light reversed all these parameters in the light treatment group. The synaptic plasticity of STZ-induced AD rats was severely affected, but flickering light prevented the loss of synaptic plasticity and activity in the light-treated AD rats. Additionally, flickering 40 Hz white light elevated the levels of mitochondrial metabolites and the current and possible opening of the mitochondrial calcium-sensitive potassium (mitoBKCa) channel which were significantly downregulated in AD rat neurons. The 40 Hz flickering light restored mitochondrial function and synaptic plasticity of AD rat neurons and improved the cognition of animals; therefore, it can be a promising strategy to reduce AD progression.
“…The baseline stimulation was restarted after the tetanic stimuli, and the recording continued for at least 60 min. Five consecutive evoked responses were averaged at 10-second intervals ( Nabavi Zadeh et al, 2023 ).…”
Section: Methodsmentioning
confidence: 99%
“…Ten consecutive evoked responses were averaged for each of them. The fEPSP slope ratio [percentage of the second fEPSP slope to the first fEPSP slope; fEPSP2/fEPSP1%] and the population spike amplitude ratio [percentage of the second population spike amplitude to the first population spike amplitude; PS2/PS1%] were determined using various interstimulus intervals ( Nabavi Zadeh et al, 2023 ).…”
Alzheimer's disease (AD) is an increasingly important public health concern due to the increasing proportion of older individuals within the general population. The impairment of processes responsible for adequate brain energy supply primarily determines the early features of the aging process. Restricting brain energy supply results in brain hypometabolism prior to clinical symptoms and is anatomically and functionally associated with cognitive impairment. The present study investigated changes in metabolic profiles induced by intracerebroventricular‐streptozotocin (ICV‐STZ) in an AD‐like animal model. To this end, male Wistar rats received a single injection of STZ (3 mg·kg−1) by ICV (2.5 μL into each ventricle for 5 min on each side). In the second week after receiving ICV‐STZ, rats were tested for cognitive performance using the Morris Water Maze test and subsequently prepared for positron emission tomography (PET) to confirm AD‐like symptoms. Tandem Mass Spectrometry (MS/MS) analysis was used to detect amino acid changes in cerebrospinal fluid (CFS) samples. Our metabolomics study revealed a reduction in the concentrations of various amino acids (alanine, arginine, aspartic acid, glutamic acid, glycine, isoleucine, methionine, phenylalanine, proline, serine, threonine, tryptophane, tyrosine, and valine) in CSF of ICV‐STZ‐treated animals as compared to controls rats. The results of the current study indicate amino acid levels could potentially be considered targets of nutritional and/or pharmacological interventions to interfere with AD progression.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.